Researchers find genetic fingerprints to predict efficacy of immunotherapy
The study, by the Israel Institute of Technology (Technion), stated that the discovery would help improve the personalisation of immunotherapy treatments, Xinhua news agency reported.
Immunotherapy is considered to be one of the greatest revolutions in cancer treatment. It enhances the immune system's ability to target and destroy cancer cells efficiently.
However, a major challenge in immunotherapy is the unpredictability of patient responses. Some patients do not benefit and may experience side effects without significant improvement.
Therefore, there is a need to identify biomarkers that can forecast the effectiveness of treatment based on the specific data of each patient.
In their study, published in the journal Cell Genomics, the team examined the genetic characteristics of T-cell clones -- groups of multiplied immune T cells that specialise in targeting a specific threat once recognised -- and their influence on treatment success.
To achieve the goal, the team conducted a large-scale meta-analysis using single-cell RNA sequencing and T-cell receptor sequencing data from cancer patients undergoing immunotherapy.
It was found that although these T-cell clones are present in both responsive and non-responsive patients, those who respond to immunotherapy display a distinct genetic signature in their T-cell clones, and the treatment boosts their immune activity.
Another major finding was that in non-responsive patients, some T-cell clones were simultaneously found both in the bloodstream and the tumour.
To achieve a better immune response, it is crucial to activating T-cell clones located solely within the tumour, rather than those present in both the tumour and the bloodstream, the researchers said.
They added that this discovery will enhance predictive capabilities and could lead to new treatment strategies that improve the effectiveness of immunotherapy.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
5 hours ago
- Hans India
Mpox deaths surpass 1,900 in Africa since 2024: Africa CDC
Addis Ababa: The death toll from Africa's ongoing mpox outbreak has surpassed 1,900 since the start of 2024, the Africa Centres for Disease Control and Prevention (Africa CDC) said. During an online media briefing, Ngashi Ngongo, chief of staff and head of the Africa CDC's Executive Office, said that 27 mpox-affected African countries have reported 174,597 cases and 1,922 related deaths since the start of last year. "When we compare the data of last year and this year, we see that in 2025, we have already reported 94,300 cases that represent 117 per cent of the cases reported last year. On the confirmed cases, we have 29,084 (this year) compared to 19,713 (last year)," Ngongo said. He noted, however, that the continent has seen a steady decline in both confirmed and suspected cases in recent weeks, especially compared to the peak in May. Increased testing coverage was also highlighted as a positive sign in the fight against the disease, Xinhua news agency reported. Mpox, formerly known as monkeypox, was first detected in laboratory monkeys in 1958. It is a rare viral disease typically transmitted through body fluids, respiratory droplets, and contaminated materials. The infection often causes fever, rash, and swollen lymph nodes. The Africa CDC declared the outbreak a public health emergency of continental security in August 2024. The World Health Organization later designated it a public health emergency of international concern. Mpox spreads from person to person mainly through close contact with someone who has mpox, including members of a household. Close contact includes skin-to-skin and mouth-to-mouth or mouth-to-skin contact, and it can also include being face-to-face with someone who has mpox (such as talking or breathing close to one another, which can generate infectious respiratory particles). Mpox causes signs and symptoms which usually begin within a week but can start 1–21 days after exposure. Symptoms typically last 2–4 weeks but may last longer in someone with a weakened immune system. Mpox causes signs and symptoms which usually begin within a week but can start 1–21 days after exposure. Symptoms typically last 2–4 weeks but may last longer in someone with a weakened immune system.
Hans India
7 hours ago
- Hans India
WHO declares Kenya free of sleeping sickness
Nairobi: The World Health Organisation (WHO) certified Kenya as having eliminated human African trypanosomiasis, also known as sleeping sickness, as a public health challenge, making it the 10th country to reach this critical milestone. "I congratulate the government and people of Kenya on this landmark achievement," said WHO Director-General Tedros Adhanom Ghebreyesus in a statement issued in Nairobi, the Kenyan capital. "Kenya joins the growing ranks of countries freeing their populations of human African trypanosomiasis. This is another step toward making Africa free of neglected tropical diseases," Tedros added. Human African trypanosomiasis is the second neglected tropical disease to be eliminated in Kenya, following the country's certification as Guinea worm disease-free in 2018. The disease is caused by protozoan parasites transmitted by infected tsetse flies, according to the WHO. Symptoms include fever, headaches, joint pain, and, in advanced stages, neurological symptoms like confusion, disrupted sleep patterns, and behavioral changes. Aden Duale, Kenya's cabinet secretary for health, said the WHO validation of sleeping sickness elimination marked a historic step toward enhancing public health security in the country, fostering economic growth. Kenya detected the first case of sleeping sickness in the early 20th century and has since engaged in robust mitigation activities. The last two exported cases were detected in 2012 in the world-famous Maasai Mara National Reserve, Xinhua news agency reported. In recent years, the country has enhanced sleeping sickness surveillance in 12 health facilities across six historically endemic counties, which serve as sentinel sites. This effort is complemented by the use of modern diagnostic tools and the training of personnel to avert new transmission. Abdourahmane Diallo, the WHO representative in Kenya, said forward-looking leadership and partnerships were pivotal in accelerating progress toward sleeping sickness elimination in the East African country. Human African trypanosomiasis, also known as sleeping sickness, is a vector-borne parasitic disease. It is caused by protozoans of the genus Trypanosoma, transmitted to humans by bites of tsetse flies (glossina) which have acquired the parasites from infected humans or animals. Tsetse flies inhabit sub-Saharan Africa and only certain species transmit the disease. Rural populations which depend on agriculture, fishing, animal husbandry or hunting are the most exposed. In many regions where tsetse flies are found, HAT is not. The disease has a focal distribution ranging from single villages to entire regions, and the incidence can vary from one village to the next.
New Indian Express
13 hours ago
- New Indian Express
Israel's plan to take over Gaza City stirs fears for civilians, hostages
Netanyahu had signaled plans for even broader war International powers, including Israeli allies France, Britain and Canada, have stepped up criticism of the war amid mounting shock over media reports showing starvation. Germany said Friday it would not authorize the export of military equipment that could be used in Gaza until further notice. Tensions could rise further if Netanyahu follows through on the more sweeping plans to take control of the entire territory, two decades after Israel's unilateral withdrawal. Israel's new plan may be aimed in part at pressuring Hamas to accept a ceasefire on Israel's terms. It may also reflect the reservations of Israel's military chief of staff, Lt. Gen. Eyal Zamir, who reportedly warned that expanding operations would endanger the remaining 20 or so living hostages held by Hamas and further strain Israel's army after nearly two years of regional wars. The military "will prepare to take control of Gaza City while providing humanitarian aid to the civilian population outside the combat zones," Netanyahu's office said in a statement after the Security Cabinet meeting. Amir Avivi, a retired brigadier general and chairman of Israel's Defense and Security Forum, estimated it would take less than three months to mobilize some 30,000 troops, evacuate Palestinian civilians and take over Gaza City. Hamas-led militants triggered the war when they stormed into Israel on Oct. 7, 2023, killing around 1,200 people and abducting 251 people. Most of the hostages have been released in ceasefires or other deals but 50 remain inside Gaza. Israel believes around 20 of them to be alive. Israel's retaliatory campaign has killed over 61,000 Palestinians, according to Gaza's Health Ministry, which does not say how many were fighters or civilians. The ministry is part of the Hamas-run government and staffed by medical professionals. The United Nations and independent experts view the ministry's figures as the most reliable estimate of casualties. Israel has disputed them without offering a toll of its own.
